4D Molecular Therapeutics, Inc. (FDMT) shares soared 11.1% in the last trading session to close at $25.79. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 3.6% loss over the past four weeks.Investors are bullish on the stock due to the recent pipeline progress. Last month, the FDA cleared the company’s investigational new drug application or 4D-175, an R100 vector-based intravitreal genetic medicine, for the treatment of patients ...